Riverbridge Partners LLC Cuts Holdings in Phreesia, Inc. $PHR

Key Points

• Riverbridge Partners LLC has reduced its stake in Phreesia, Inc. by 13.1%, now holding approximately 551,522 shares valued at $15.7 million as of their latest SEC filing.
• Phreesia reported a quarterly earnings result of $0.01 per share, surpassing estimates significantly, with a 14.9% year-over-year revenue increase to $117.26 million.
• Multiple research firms, including Piper Sandler and Raymond James, have recently upgraded Phreesia, setting targets as high as $34.00 and giving it a consensus rating of "Buy."

Riverbridge Partners LLC decreased its stake in shares of Phreesia, Inc. (NYSE:PHR - Free Report) by 13.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 551,522 shares of the company's stock after selling 82,874 shares during the quarter. Riverbridge Partners LLC owned approximately 0.93% of Phreesia worth $15,696,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. KBC Group NV purchased a new position in shares of Phreesia in the 1st quarter valued at about $74,000. Farther Finance Advisors LLC increased its holdings in shares of Phreesia by 9,375.0% in the 2nd quarter. Farther Finance Advisors LLC now owns 3,032 shares of the company's stock valued at $86,000 after acquiring an additional 3,000 shares during the last quarter. CWM LLC increased its holdings in shares of Phreesia by 994.9% in the 1st quarter. CWM LLC now owns 4,040 shares of the company's stock valued at $103,000 after acquiring an additional 3,671 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Phreesia by 53.0% in the 1st quarter. Smartleaf Asset Management LLC now owns 5,267 shares of the company's stock valued at $137,000 after acquiring an additional 1,825 shares during the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Phreesia by 10,605.7% in the 1st quarter. GAMMA Investing LLC now owns 5,674 shares of the company's stock valued at $145,000 after acquiring an additional 5,621 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Phreesia Stock Performance

Phreesia stock opened at $23.66 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.12 and a current ratio of 2.12. The stock has a fifty day moving average of $27.38 and a two-hundred day moving average of $26.36. The company has a market capitalization of $1.42 billion, a price-to-earnings ratio of -56.34 and a beta of 0.72. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $32.76.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings results on Thursday, September 4th. The company reported $0.01 earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.08. The company had revenue of $117.26 million during the quarter, compared to the consensus estimate of $116.39 million. Phreesia had a negative return on equity of 8.75% and a negative net margin of 5.35%.Phreesia's revenue was up 14.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.03) earnings per share. Phreesia has set its FY 2026 guidance at EPS. On average, analysts anticipate that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on PHR. Piper Sandler raised their price target on Phreesia from $33.00 to $34.00 and gave the stock an "overweight" rating in a research note on Friday, September 5th. Raymond James Financial set a $33.00 price target on Phreesia and gave the stock an "outperform" rating in a research note on Friday, September 5th. Citigroup restated an "outperform" rating on shares of Phreesia in a research note on Monday, September 8th. DA Davidson upgraded Phreesia to a "strong-buy" rating in a research note on Monday, September 8th. Finally, JMP Securities increased their price objective on Phreesia from $30.00 to $34.00 and gave the stock a "market outperform" rating in a research report on Monday, September 8th. One investment analyst has rated the stock with a Strong Buy rating and twelve have assigned a Buy rating to the company's stock. According to MarketBeat, Phreesia currently has a consensus rating of "Buy" and an average target price of $34.08.

Insider Activity at Phreesia

In other Phreesia news, Director Mark Douglas Smith sold 7,000 shares of the business's stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $29.00, for a total transaction of $203,000.00. Following the transaction, the director owned 37,353 shares in the company, valued at $1,083,237. The trade was a 15.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Allison C. Hoffman sold 3,133 shares of the business's stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $23.28, for a total value of $72,936.24. Following the transaction, the general counsel owned 139,037 shares in the company, valued at approximately $3,236,781.36. This represents a 2.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 125,541 shares of company stock valued at $3,661,812 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.